New Veterinary Painkiller Threatens South Asia’s Vultures – Lessons from the Diclofenac Crisis

Conservationists are raising the alarm after research published in Science links ketoprofen – a veterinary anti-inflammatory increasingly used on cattle – to fresh mortality events among scavenging birds in South Asia. Once-valiant efforts to restore vulture populations after the diclofenac disaster of the 1990s and 2000s could be undermined if regulators and veterinarians do not act quickly. Like its notorious predecessor diclofenac, ketoprofen can persist in livestock carcasses and deliver lethal doses to birds that feed on them, accelerating renal collapse in already imperiled species.

From catastrophe to cautious recovery: the diclofenac precedent

Two decades ago, the widespread veterinary use of diclofenac triggered population crashes of more than 95% in several Gyps vulture species across the Indian subcontinent. These apex scavengers – such as the white-rumped, Indian, and slender-billed vultures – were pushed to the brink, and many populations remain classified as Critically Endangered by the IUCN. The crisis spurred unprecedented conservation responses: emergency bans on diclofenac in veterinary formulations, captive-breeding and release programs, the creation of “vulture restaurants” (safe carcass provisioning sites), and the promotion of meloxicam as a proven vulture-safe analgesic.

Those interventions reduced immediate mortality and enabled some fragile recoveries, but the rebound has been uneven and slow. The memory of diclofenac shows how a single veterinary drug can cascade through ecosystems, harming public health, livestock economies, and traditional carcass-cleaning services provided free by vultures.

Ketoprofen: emerging evidence and why it matters

Recent field necropsies and residue analyses implicate ketoprofen in new vulture deaths across parts of India, Nepal, and Bangladesh. Scientists report drug residues in cattle carcasses and pathology consistent with non-steroidal anti-inflammatory drug (NSAID)-induced kidney failure in affected birds. Although ketoprofen was introduced as an alternative painkiller, accumulating data indicate it can be toxic to Gyps vultures at realistic exposure levels.

Why this is urgent:

• Vulture populations are still low compared with pre-crisis baselines; a fresh wave of mortality could erase decades of conservation investment.
• Ketoprofen remains available through veterinary suppliers and, in many rural areas, over the counter – increasing the chance of livestock carcasses contaminated with the drug entering the food web.
• Regulatory frameworks in the region often focus on livestock productivity and short-term efficacy, with limited requirements to assess wider ecological impacts on scavengers.

How authorities and communities are responding

Environment and veterinary departments across South Asia have begun reviewing approvals for ketoprofen and are under pressure to introduce tighter controls. Proposed actions being discussed by scientists and policymakers include rapid restrictions on veterinary ketoprofen use in high-risk districts, mandatory labeling about wildlife risks, and enhanced surveillance of unexplained vulture mortality around abattoirs and carcass sites.

On the ground, conservation groups are scaling up awareness programs for rural veterinarians and livestock owners, expanding vulture-safe carcass provisioning, and accelerating rescue and rehabilitation for affected birds. Captive-breeding centers that helped prevent extinctions after the diclofenac crisis are preparing to receive more individuals should mass-mortality events increase.

Policy and practice: a roadmap to prevent repeat disasters

Experts are advocating a multi-layered approach that reconciles animal health needs with ecosystem protection. Key recommendations include:

• Mandatory wildlife-risk screening: Require pre-approval toxicity testing of new and repurposed veterinary NSAIDs on surrogate scavenger species or validated models.
• Targeted restrictions: Impose bans or strict controls on high-risk drugs in areas with remaining Gyps populations, coupled with enforcement at the point of sale.
• Promote proven alternatives: Scale up access to and subsidies for vulture-safe medicines such as meloxicam where scientifically appropriate.
• Information systems: Create rapid-reporting networks linking farmers, veterinarians, conservationists, and regulators to flag sudden bird deaths and contaminated carcasses in real time.
• Incentives and education: Offer training and financial incentives to farmers who adopt safe practices, and launch behavior-change campaigns that explain the ecological and economic value of vultures.
• Carcass management innovations: Expand “vulture restaurants,” organized carcass disposal programs, and carcass-treatment protocols that remove toxic residues before exposure to scavengers.

Practical measures already working

In several regions, subsidized distribution of meloxicam, community-run vulture feeding sites, and active collaboration between wildlife NGOs and veterinary authorities have reduced exposure risk. These interventions demonstrate that combining regulation with on-the-ground incentives can produce measurable benefits for both livelihoods and biodiversity.

Comparing drug risks: a simplified guide for policymakers

Why rapid action matters – and what’s at stake

Vultures are nature’s sanitation workers: by consuming carcasses quickly, they limit the spread of livestock pathogens and reduce the need for costly carcass disposal. Losing more vultures would create both ecological and public-health costs. The diclofenac episode taught policymakers that regulatory inaction has long-term consequences; ketoprofen’s emergence shows those lessons remain relevant.

Time is a limiting factor. With some Gyps species still hovering at a fraction of their historical numbers, even localized upticks in drug-related mortality can have outsized impacts on population viability. Conversely, decisive measures – a mix of smarter regulation, farmer engagement, and conservation interventions – can prevent another collapse and secure the modest recovery already underway.

Conclusion: turning scientific warning into protective policy

The evidence linking ketoprofen to vulture fatalities is a stark reminder that veterinary drugs do not act only on treated animals. They ripple outward through ecosystems, sometimes with devastating effects. Policymakers, veterinary authorities, and rural communities must treat this as an urgent policy problem: reassess drug approvals, close regulatory loopholes, expand access to known-safe alternatives, and strengthen surveillance at carcass hotspots. If these steps are taken swiftly and collaboratively, Asia’s vultures still have a chance to recover; if not, the region risks repeating a conservation catastrophe that science had hoped to prevent.